What research findings exist regarding ARA-290 in small fiber neuropathy and nerve repair?
ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery. Additionally, some studies report increased corneal and skin small nerve fiber indicators at certain dosage levels.[1] ↗ [2] ↗
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2025 · PMID 40216181 | Rat sciatic nerve crush model and Schwann cells | ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery. | Preclinical peripheral nerve injury, not equivalent to treatment effects in human small fiber neuropathy. |
| 2017 · PMID 28475703 | 64 patients with sarcoidosis-related small fiber neuropathy; 28-day Phase IIb randomized trial. | Specific dosage group showed increased corneal and skin small nerve fiber indices. | Nerve fibers used as surrogate endpoint; no significant pain group difference, cannot be claimed as proven pain relief. |
| 2015 · PMID 25387363 | Type 2 diabetes with neuropathy; 28 days ARA290 or placebo, 56 days follow-up | Improvement of neurodegenerative symptoms and some metabolic indicators, increased corneal nerve fiber metrics in some patients. | Small Phase II studies, targeted populations, and short follow-up; Not equivalent to general neuroregeneration commitments. |
| 2013 · PMID 24136731 | Nodular small fiber neuropathy; 28-day blinded placebo-controlled study | Improvement in neurological symptoms, corneal nerve fiber density, and some motor function indicators. | Historical small-sample studies cannot be described as general neural repair or cure. |
References
How are inflammation and functional recovery after sciatic nerve injury?
ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery.[1] ↗
Rat sciatic nerve crush model and Schwann cells
Preclinical peripheral nerve injury, not equivalent to treatment effects in human small fiber neuropathy.
View the Article Title and Full Citation＋
ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury.
European Journal of Pharmacology · Volume and Issue Year 2025
First published 2025-04-09 · PMID 40216181
DOI 10.1016/j.ejphar.2025.177610
Are nerve fiber structure and pain endpoints consistent?
Specific dosage group showed increased corneal and skin small nerve fiber indices.[2] ↗
64 patients with sarcoidosis-related small fiber neuropathy; 28-day Phase IIb randomized trial.
Nerve fibers used as surrogate endpoint; no significant pain group difference, cannot be claimed as proven pain relief.
View the Article Title and Full Citation＋
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.
Investigative Ophthalmology & Visual Science · Volume/Issue/Year 2017
First published 2017-05-01 · PMID 28475703
DOI 10.1167/iovs.16-21291
What has been observed in studies of diabetic neuropathy?
Improvement of neurodegenerative symptoms and some metabolic indicators, increased corneal nerve fiber metrics in some patients.[3] ↗
Type 2 diabetes with neuropathy; 28 days ARA290 or placebo, 56 days follow-up
Small Phase II studies, targeted populations, and short follow-up; Not equivalent to general neuroregeneration commitments.
View the Article Title and Full Citation＋
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Molecular medicine (Cambridge, Mass.) · Volume/Issue Year 2015
First published on 2015-03-13 · PMID 25387363
DOI 10.2119/molmed.2014.00215
What research clues are there for sarcoidosis-related neurological symptoms?
Improvement in neurological symptoms, corneal nerve fiber density, and some motor function indicators.[4] ↗
Nodular small fiber neuropathy; 28-day blinded placebo-controlled study
Historical small-sample studies cannot be described as general neural repair or cure.
View the Article Title and Full Citation＋
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Molecular medicine (Cambridge, Mass.) · Volume/Issue Year 2013
First published on 2013-11-08 · PMID 24136731
DOI 10.2119/molmed.2013.00122
Common issues and corresponding evidence
What research findings exist regarding ARA-290 in small fiber neuropathy and nerve repair?＋
ARA290 inhibits early inflammation and NLRP3-related activation and promotes functional recovery. Additionally, some studies report increased corneal and skin small nerve fiber indicators at certain dosage levels.[1] ↗ [2] ↗
Does an increase in nerve fibers from ARA-290 necessarily mean pain relief?＋
Not equal. In a Phase IIb study, specific group corneal small nerve fiber indices increased, but the placebo-corrected differences in pain were not significant; structural indices and symptoms should be stated separately.[2] ↗
ARA-290—these conclusions apply to which study populations?＋
Rat sciatic nerve crush model and Schwann cells; 64 patients with sarcoidosis-related small fiber neuropathy; 28-day Phase IIb randomized trial; type 2 diabetes with neuropathy; 28 days ARA290 or placebo, 56 days observation. Preclinical peripheral nerve injury, not equivalent to human small fiber neuropathy treatment effect.[1] ↗ [2] ↗ [3] ↗
ARA-290
Return to catalog specifications and batch file verification entry.
